Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical Investigation
J Clin Invest. 1983 August; 72(2): 648–655.
PMCID: PMC1129224

Metabolic compensation for profound erythrocyte adenylate kinase deficiency. A hereditary enzyme defect without hemolytic anemia.


A child with hemolytic anemia was found to have severe erythrocyte adenylate kinase (AK) deficiency, but an equally enzyme-deficient sibling had no evidence of hemolysis. No residual enzyme activity was found in erythrocytes by spectrophotometric methods that could easily have detected 0.1% of normal activity. However, concentrated hemolysates were shown to have the capacity to generate small amounts of ATP and AMP from ADP after prolonged incubation. Hemolysates could also catalyze the transfer of labeled gamma-phosphate from ATP to ADP. Intact erythrocytes were able to transfer phosphate from the gamma-position of ATP to the beta-position, albeit at a rate substantially slower than normal. They could also incorporate 14C-labeled adenine into ADP and ATP. Thus, a small amount of residual AK-like activity representing about 1/2,000 of the activity normally present could be documented in the deficient erythrocytes. The residual activity was not inhibited by N-ethylmaleimide, which completely abolishes the activity of the normal AK1 isozyme of erythrocytes. The minute amount of residual activity in erythrocytes could represent a small amount of the AK2 isozyme, which has not been thought to be present in erythrocytes, or the activity of erythrocyte guanylate kinase with AMP substituting as substrate for GMP. Peripheral blood leukocytes, cultured skin fibroblasts, and transformed lymphoblasts from the deficient subject manifested about 17, 24, and 74%, respectively, of the activity of the concurrent controls. This residual activity is consistent with the existence of genetically independent AK isozyme, AK2, which is known to exist in these tissues. The cause of hemolysis in the proband was not identified. Possibilities include an unrelated enzyme deficiency or other erythrocyte enzyme defect and intraction of another unidentified defect with AK deficiency.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.1M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Beutler E, Guinto E. A simple, rapid, efficient method for the preparation of gamma 32P-labeled guanosine triphosphate (GTP) and adenosine triphosphate (ATP). J Lab Clin Med. 1976 Sep;88(3):520–524. [PubMed]
  • Beutler E, West C, Blume KG. The removal of leukocytes and platelets from whole blood. J Lab Clin Med. 1976 Aug;88(2):328–333. [PubMed]
  • BARTLETT GR. Methods for the isolation of glycolytic intermediated by column chromatography with ion exchange resins. J Biol Chem. 1959 Mar;234(3):459–465. [PubMed]
  • Slaughter L, Carson DA, Jensen FC, Holbrook TL, Vaughan JH. In vitro effects of Epstein-Barr virus on peripheral blood mononuclear cells from patients with rheumatoid arthritis and normal subjects. J Exp Med. 1978 Nov 1;148(5):1429–1434. [PMC free article] [PubMed]
  • Beutler E, Guinto E, Kuhl W, Matsumoto F. Existence of only a single functional pool of adenosine triphosphate in human erythrocytes. Proc Natl Acad Sci U S A. 1978 Jun;75(6):2825–2828. [PubMed]
  • Szeinberg A, Gavendo S, Cahane D. Erythrocyte adenylate-kinase deficiency. Lancet. 1969 Feb 8;1(7589):315–316. [PubMed]
  • Boivin P, Galand C, Hakim J, Simony D, Seligman M. Une nouvelle érythroenzymopathie: anémie hémolytique congénitale non sphérocytaire et déficit héréditaire en adénylate-kinase érytrocytaire. Presse Med. 1971 Jan 30;79(6):215–218. [PubMed]
  • Boivin P, Galand C, Hakim J, Simony D, Seligman M. Déficit congénital en adénylate-kinase érythrocytaire. Presse Med. 1970 Jun;78(32):1443–1443. [PubMed]
  • Boivin P, Galand C, Demartial MC. Erythroenzymopathies acquises. II. Déficit en adénylate-kinase au cours des hémopathies. Pathol Biol (Paris) 1972 Oct;20(19):781–784. [PubMed]
  • Beutler E. Red cell enzyme defects as nondiseases and as diseases. Blood. 1979 Jul;54(1):1–7. [PubMed]
  • Bartlett GR. Phosphorus compounds in the human erythrocyte. Biochim Biophys Acta. 1968 Mar 11;156(2):221–230. [PubMed]
  • McKusick VA, Ruddle FH. The status of the gene map of the human chromosomes. Science. 1977 Apr 22;196(4288):390–405. [PubMed]
  • Wilson DE, Povey S, Harris H. Adenylate kinases in man: evidence for a third locus. Ann Hum Genet. 1976 Jan;39(3):305–313. [PubMed]
  • Khoo JC, Russell PJ. Isoenzymes of adenylate kinase in human tissue. Biochim Biophys Acta. 1972 Apr 7;268(1):98–101. [PubMed]
  • Agarwal KC, Parks RE., Jr Adenosine triphosphate-guanosine 5'-phosphate phosphotransferase. IV. Isozymes in human erythrocytes and Sarcoma 180 ascites cells. Mol Pharmacol. 1972 Mar;8(2):128–138. [PubMed]
  • Russell PJ, Jr, Horenstein JM, Goins L, Jones D, Laver M. Adenylate kinase in human tissue. I. Organ specificity of adenylate kinase isoenzymes. J Biol Chem. 1974 Mar 25;249(6):1874–1879. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation